SK287992B6 - Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction - Google Patents

Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction Download PDF

Info

Publication number
SK287992B6
SK287992B6 SK508-2003A SK5082003A SK287992B6 SK 287992 B6 SK287992 B6 SK 287992B6 SK 5082003 A SK5082003 A SK 5082003A SK 287992 B6 SK287992 B6 SK 287992B6
Authority
SK
Slovakia
Prior art keywords
ubiquinone
ppar
activator
fenofibrate
composition
Prior art date
Application number
SK508-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5082003A3 (en
Inventor
Gerald Watts
David Playford
Original Assignee
Fournier Laboratories Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPR1038A external-priority patent/AUPR103800A0/en
Priority claimed from AUPR3424A external-priority patent/AUPR342401A0/en
Application filed by Fournier Laboratories Ireland Limited filed Critical Fournier Laboratories Ireland Limited
Publication of SK5082003A3 publication Critical patent/SK5082003A3/sk
Publication of SK287992B6 publication Critical patent/SK287992B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK508-2003A 2000-10-26 2001-10-23 Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction SK287992B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPR1038A AUPR103800A0 (en) 2000-10-26 2000-10-26 Compositions for the treatment of endothelial dysfunction
AUPR3424A AUPR342401A0 (en) 2001-02-28 2001-02-28 Compositions for the treatment of endothelial dysfunction
PCT/EP2001/012425 WO2002034259A1 (fr) 2000-10-26 2001-10-23 Combinaison de fenofibrate et de coenzyme q10 permettant de traiter un dysfonctionnement endothelial

Publications (2)

Publication Number Publication Date
SK5082003A3 SK5082003A3 (en) 2003-11-04
SK287992B6 true SK287992B6 (sk) 2012-09-03

Family

ID=25646491

Family Applications (1)

Application Number Title Priority Date Filing Date
SK508-2003A SK287992B6 (sk) 2000-10-26 2001-10-23 Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction

Country Status (30)

Country Link
US (1) US7410983B2 (fr)
EP (1) EP1328266B1 (fr)
JP (1) JP4236464B2 (fr)
KR (1) KR100862129B1 (fr)
CN (1) CN1220488C (fr)
AR (1) AR035071A1 (fr)
AT (1) ATE316787T1 (fr)
AU (1) AU2176502A (fr)
BG (1) BG65979B1 (fr)
BR (1) BR0114701A (fr)
CA (1) CA2426625C (fr)
CY (1) CY1105007T1 (fr)
CZ (1) CZ301282B6 (fr)
DE (1) DE60117046T2 (fr)
DK (1) DK1328266T3 (fr)
DZ (1) DZ3442A1 (fr)
EE (1) EE05281B1 (fr)
ES (1) ES2257457T3 (fr)
HK (1) HK1057340A1 (fr)
HU (1) HUP0303566A3 (fr)
IL (2) IL155524A0 (fr)
MA (1) MA25847A1 (fr)
MX (1) MXPA03003733A (fr)
NO (1) NO332260B1 (fr)
PL (1) PL212952B1 (fr)
PT (1) PT1328266E (fr)
RU (1) RU2003111175A (fr)
SK (1) SK287992B6 (fr)
TN (1) TNSN01151A1 (fr)
WO (1) WO2002034259A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1408950B1 (fr) 2001-07-11 2007-04-25 Boehringer Ingelheim Pharmaceuticals Inc. Methodes permettant de traiter des maladies induites par les cytokines
CA2481371A1 (fr) * 2002-03-11 2003-09-18 Peter Zahradka Utilisation d'agonistes de ppar alpha dans le traitement de maladies vasculaires et renales
US20070225614A1 (en) 2004-05-26 2007-09-27 Endothelix, Inc. Method and apparatus for determining vascular health conditions
FR2845602B1 (fr) * 2002-10-11 2005-07-08 Servier Lab Association entre un ligand des recepteurs actives par les proliferateurs de peroxisomes et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
JP2005104951A (ja) * 2003-01-17 2005-04-21 Kirin Brewery Co Ltd 血圧降下用組成物および血管柔軟性改善用組成物並びにこれらの機能が付与された食品
FR2868313B1 (fr) * 2004-03-31 2008-08-15 Servier Lab Nouvelle association entre un compose heterocyclique et un agent antioxydant et les compositions pharmaceutiques qui les contiennent
EP1621200A1 (fr) * 2004-07-26 2006-02-01 Fournier Laboratories Ireland Limited Combinaison pharmaceutique comprenant un inhibiteur de l'aggregation des thrombocytes et un fibrate
DK2564843T3 (en) 2005-06-01 2019-03-11 Bioelectron Tech Corp Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers
EP1785133A1 (fr) * 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Utilisation du fenofibrate ou d'un de ses dérivés pour la prevention de la retinopathie diabetique
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
WO2007106912A2 (fr) * 2006-03-16 2007-09-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Agonistes du récepteur-alpha activé de la prolifération des peroxysomes pour la conservation d'organe
US20070225606A1 (en) * 2006-03-22 2007-09-27 Endothelix, Inc. Method and apparatus for comprehensive assessment of vascular health
US20080027330A1 (en) * 2006-05-15 2008-01-31 Endothelix, Inc. Risk assessment method for acute cardiovascular events
US20080081963A1 (en) * 2006-09-29 2008-04-03 Endothelix, Inc. Methods and Apparatus for Profiling Cardiovascular Vulnerability to Mental Stress
KR100989093B1 (ko) 2008-01-18 2010-10-25 한화제약주식회사 생강나무 가지의 추출물을 포함하는 심혈관계 질환의 예방 및 치료용 조성물
US8314153B2 (en) 2008-09-10 2012-11-20 Edison Pharmaceuticals, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
EP2391219A4 (fr) * 2009-01-29 2013-03-06 Joshua D Levine Procédé d'ajout d'agents botaniques/de suppléments de régime à des agents pharmaceutiques dans un régime pharmacothérapeutique
US8973851B2 (en) * 2009-07-01 2015-03-10 The Procter & Gamble Company Apparatus and methods for producing charged fluid droplets
EP2551255B1 (fr) * 2010-03-26 2017-11-08 Vivacell Biotechnology España, S.L Dérivés quinone de cannabinoïdes
RU2554500C2 (ru) * 2013-09-20 2015-06-27 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Способ лечения ишемического инсульта
CN108712903A (zh) 2015-12-17 2018-10-26 生物电子技术有限公司 用于治疗氧化应急障碍的氟烷基、氟代烷氧基、苯氧基、杂芳氧基、烷氧基和胺1,4-苯醌衍生物
WO2019084540A1 (fr) 2017-10-27 2019-05-02 Zeta Biolongevity, Inc. Compositions et méthodes pour traiter et prévenir la protéinurie et l'érosion endothéliale
CN110907407B (zh) * 2019-12-03 2022-02-25 东北石油大学 一种基于spr的高灵敏度光子准晶体光纤折射率传感器

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229385A (en) * 1986-01-30 1993-07-20 Takeda Chemical Industries, Ltd. Quinone derivatives, their production and use
FR2627696B1 (fr) 1988-02-26 1991-09-13 Fournier Innovation Synergie Nouvelle forme galenique du fenofibrate
FI102273B (fi) 1989-09-11 1998-11-13 Eisai Co Ltd Kinonijohdannaiset, niiden valmistaminen ja niiden farmakologinen käyt tö
FR2730231B1 (fr) * 1995-02-02 1997-04-04 Fournier Sca Lab Association de fenofibrate et de vitamine e, utilisation en therapeutique
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP1034791A1 (fr) * 1997-11-28 2000-09-13 Nikolai Vasilievich Karsanov Produit anti-hypoxique et anti-ischemique
US6423742B1 (en) * 1999-09-02 2002-07-23 Drake Larson Compositions for reducing vascular plaque formation and methods of using same

Also Published As

Publication number Publication date
EE05281B1 (et) 2010-04-15
EP1328266B1 (fr) 2006-02-01
NO20031851L (no) 2003-06-24
US20040022778A1 (en) 2004-02-05
CA2426625A1 (fr) 2002-05-02
NO20031851D0 (no) 2003-04-24
TNSN01151A1 (en) 2005-11-10
MXPA03003733A (es) 2004-10-15
EP1328266A1 (fr) 2003-07-23
BR0114701A (pt) 2003-11-18
MA25847A1 (fr) 2003-07-01
PL212952B1 (pl) 2012-12-31
CN1471390A (zh) 2004-01-28
DZ3442A1 (fr) 2002-05-02
CY1105007T1 (el) 2009-11-04
PL361635A1 (en) 2004-10-04
AR035071A1 (es) 2004-04-14
JP2004512302A (ja) 2004-04-22
HK1057340A1 (en) 2004-04-02
CA2426625C (fr) 2010-06-01
NO332260B1 (no) 2012-08-13
ATE316787T1 (de) 2006-02-15
IL155524A0 (en) 2003-11-23
HUP0303566A3 (en) 2005-05-30
CZ301282B6 (cs) 2009-12-30
CN1220488C (zh) 2005-09-28
DE60117046D1 (de) 2006-04-13
BG107765A (bg) 2004-02-27
ES2257457T3 (es) 2006-08-01
DK1328266T3 (da) 2006-06-06
KR100862129B1 (ko) 2008-10-09
RU2003111175A (ru) 2004-09-10
JP4236464B2 (ja) 2009-03-11
US7410983B2 (en) 2008-08-12
DE60117046T2 (de) 2006-09-28
IL155524A (en) 2008-08-07
SK5082003A3 (en) 2003-11-04
BG65979B1 (bg) 2010-08-31
WO2002034259A1 (fr) 2002-05-02
EE200300165A (et) 2003-06-16
PT1328266E (pt) 2006-05-31
AU2176502A (en) 2002-05-06
HUP0303566A2 (hu) 2004-03-01
KR20030055276A (ko) 2003-07-02

Similar Documents

Publication Publication Date Title
SK287992B6 (sk) Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction
AU705002B2 (en) Method and formulation of stimulating nitric oxide synthesis
EP1653978B1 (fr) Utilisation de sels de nitrite pour le traitement de troubles cardiovasculaires
US6231894B1 (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
JP2004503585A (ja) 薬剤混合物
KR20010102183A (ko) 심혈관 사고 예방용 필수 지방산
EA022166B1 (ru) Синтетические тритерпеноиды и их применение в лечении заболеваний
US20060228403A1 (en) Nutritional supplements for cardiovascular health
EP1466602A1 (fr) Inhibiteurs de fibrose des organes
US11337960B2 (en) Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
JP2016130265A (ja) 生体内のメイラード反応抑制剤またはＡＧＥｓ生成抑制剤
RU2387448C2 (ru) Незаменимые жирные кислоты, предназначенные для предупреждения и/или лечения депрессии у пациентов, страдающих коронарной болезнью сердца или болезнью коронарной артерии
AU2002221765A1 (en) Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction
Bourde et al. Controlled Clinical Trial Of An Antiaggregating Agent, Ti-Clopidine, In Vascular Ulcers Of The Leg
US20200390841A1 (en) Compositions and methods for treating wounds
WO2002094018A1 (fr) Compositions a base de d-chiro inositol et de composes hypolipidemiants et methodes therapeutiques les utilisant
CA2052577C (fr) Usages therapeutiques de l'acide eicosapentanoique
ZA200303126B (en) Combination of fenofibrate and coenzyme Q10 for the treatment of endothelial dysfunction.
US20040147600A1 (en) Pharmaceutical combination comprising either (s)-2-ethoxy-3 [4-(2-{4-methane sulfonyl oxyphenyl} ethoxy)phenyl]propanoic acid or 3-{4-[2-(4-tert-butoxy carbonylamino phenyl)ethoxy]phenyl}-(s-2ethoxy propanoic acid and insulin
UA128573C2 (uk) Способи лікування підвищення маси тіла, індукованого антипсихотичними засобами, за допомогою мірикориланту
US6323203B1 (en) Composition and method for treating diabetes
AU2740500A (en) Composition and method for treating diabetes